Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distr
| Current Price | ₹975.55 |
|---|---|
| Market Cap | ₹15,452 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 38.9 |
| Return on Equity | 5.96% |
| Beta (1Y) | 0.82 |
| Dividend Yield | 0.51% |
1. Radio Pharma-44.6% 2. Allergy Immunotherapy-9.6% 3. Contract Development and Manufacturing Organization - Sterile Injectables-21.9% 4. Contract Research, Development and Manufacturing Organization-15.3% 5. Generics-9.3% 7. Unallocable Corporate-0.7%
Jubilant Pharmova Ltd is trading at ₹975.55, with a market capitalisation of ₹15,452 Cr.
Jubilant Pharmova Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Jubilant Pharmova Ltd has a P/E of 38.9 and a return on equity of 5.96%.